Application of quantitative analysis of extraocular muscles to evaluate the inflammatory activity of thyroid associated ophthalmopathy
-
摘要:
目的 评估99mTc-DTPA眼眶SPECT/CT显像眼外肌定量分析技术在甲状腺相关眼病(TAO)炎性活动性的临床应用价值。 方法 回顾性分析我院行99mTc-DTPA眼眶SPECT/CT显像检查的44例TAO患者,按照临床活动性评分(CAS)将TAO患者分为活动期组(CAS≥3,n=23)和非活动期组(CAS < 3,n=21)。在99mTc-DTPA眼眶SPECT/CT衰减校正图像中,选择眼外肌区域中摄取放射性核素最多的图像层面,分别勾画双侧眼外肌的感兴趣区,测量其放射性计数最大值,选取视神经水平枕叶脑组织的感兴趣区作为本底,计算眼外肌与视神经水平枕叶脑组织显像剂摄取比值(UR),同时将每侧UR值最高的眼外肌作为炎症程度受累最为严重的眼外肌,选取URmax值比较其组间差异,以评价对TAO活动性的诊断效能。 结果 活动期TAO患者的眼外肌URmax高于非活动期TAO患者,差异有统计学意义(P < 0.05)。TAO患者的眼外肌URmax与其CAS呈正相关关系(r=0.799, P < 0.05);在评估TAO临床活动性方面,眼外肌URmax和CAS具有一致性(Kappa值=0.915, P < 0.05);ROC曲线下面积为0.975,区分活动期与非活动期的URmax阈值为5.2,其敏感度为87.5%,特异性为100%。 结论 本研究所使用眼外肌定量分析技术的测量方法能够直接显示每条眼外肌的炎性反应,可准确定位受累的眼外肌,使双侧眼外肌靶区勾画更加精准,还可以测量各眼外肌的放射性核素摄取比值即UR值,能够更加准确地评估TAO的炎症活动性程度。 -
关键词:
- 甲状腺相关性眼病 /
- 99m锝-二乙烯三胺五乙酸 /
- SPECT/CT /
- 眼外肌与视神经水平枕叶脑组织显像剂摄取比值 /
- 临床活动性评分
Abstract:Objective To assess the clinical value of the 99mTc-DTPA orbital SPECT/CT imaging technique for quantitative analysis of extraocular muscles in the inflammatory activity of thyroid associated ophthalmopathy (TAO). Methods Forty-four patients with TAO who underwent 99mTc-DTPA orbital SPECT/CT imaging in our hospital were retrospectively analyzed, and the patients with TAO were classified into an active group [clinical activity score (CAS)≥3] and an inactive group (CAS < 3) according to CAS scores, with 23 patients (46 eyes) in the active group and 21 patients (42 eyes) in the inactive group. In the consensus on SPECT images corrected for CT attenuation, the uptake values were determined by placing a region of interest within the area of the highest uptake in each extraocular muscle. To determine the background uptake values, a circular region of interest was placed on the occipital lobe at the level of the optic nerve. The UR was calculated as the ratio of the maximum uptake value in the region of interest to the maximum uptake value in the background. And the highest UR value of extraocular muscles was considered as the most severely involved extraocular muscle. The URmax value of extraocular muscles was selected for statistical analysis of intergroup variability, which was used to evaluate the diagnostic efficacy for the diagnosis of TAO activity. Results The URmax of the extraocular muscles was significantly higher in patients with active TAO than inactive TAO, and the difference was statistically significant. (P < 0.05). The results showed a significant correlation between the URmax and CAS (r=0.799, P < 0.05). The URmax of the extraocular muscles and CAS were in agreement in assessing the clinical activity of TAO (Kappa value=0.915, P < 0.05); The area under the ROC curve was 0.975, and the URmax threshold for distinguishing between active and inactive periods was 5.2, with a sensitivity of 87.5% and a specificity of 100%. Conclusion The measurements of quantitative extra-ocular muscles analysis technique used in this study is able to directly show the inflammatory response of extra-ocular muscles, which can accurately localize the involved extra-ocular muscles and enable more precise outlining region of interest, as well as measure the uptake ratio of each extra-ocular muscle, and more accurately assess the degree of inflammatory. -
表 1 活动期与非活动期TAO患者的URmax比较
Table 1. Comparison of URmax of extraocular muscles between active and inactive TAO patients
Index Active TAO (n=23) Inactive TAO (n=21) P Female [n(%)] 11(47.8) 12(57.1) 0.563 Age (year, Mean±SD) 39.67±15.017 38.28±14.392 0.718 Smoker [n(%)] 7(30.4) 6(28.6) 0.817 URmax(Mean±SD) 7.0318±2.05644 3.8238±0.63080 < 0.001 -
[1] Bahn RS. Graves'ophthalmopathy[J]. N Engl J Med, 2010, 362(8): 726-38. doi: 10.1056/NEJMra0905750 [2] Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European thyroid association/European group on Graves' orbitopathy guidelines for the management of Graves' orbitopathy[J]. Eur Thyroid J, 2016, 5(1): 9-26. doi: 10.1159/000443828 [3] Riguetto CM, Neto AM, Tambascia MA, et al. The relationship between quality of life, cognition, and thyroid status in Graves'disease[J]. Endocrine, 2019, 63(1): 87-93. doi: 10.1007/s12020-018-1733-y [4] Bhatti MT, Dutton JJ. Thyroid eye disease[J]. J Neuro Ophthalmol, 2014, 34(2): 186-97. doi: 10.1097/WNO.0000000000000128 [5] Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European thyroid association/European group on Graves' orbitopathy guidelines for the management of Graves' orbitopathy[J]. Eur Thyroid J, 2016, 5(1): 9-26. doi: 10.1159/000443828 [6] 汤玮, 石勇铨. 影像学检查对甲状腺相关眼病诊断和病情评估的价值[J]. 中国实用内科杂志, 2015, 35(7): 572-6. https://www.cnki.com.cn/Article/CJFDTOTAL-SYNK201507006.htm [7] 刘洲君, 刘超. 甲状腺相关性眼病影像学诊断的研究进展[J]. 江苏医药, 2015, 41(6): 691-3. doi: 10.19460/j.cnki.0253-3685.2015.06.027 [8] 姜虹, 燕飞, 鲜军舫, 等. T2mappiing MRI评估甲状腺相关性眼病免疫抑制疗效的初步研究[J]. 眼科, 2018, 27(5): 339-43. doi: 10.3760/cma.j.issn.0412-4081.2018.05.006 [9] Galuska L, Leovey A, Szucs-Farkas Z, et al. SPECT using 99mTc-DTPA for the assessment of disease activity in Graves'ophthalmopathy: a comparison with the results from MRI[J]. Nucl Med Commun, 2002, 23(12): 1211-6. doi: 10.1097/00006231-200212000-00010 [10] Čivrný J, Karhanová M, Hübnerová P, et al. MRI in the assessment of thyroid-associated orbitopathy activity[J]. Clin Radiol, 2022, 77(12): 925-34. doi: 10.1016/j.crad.2022.08.124 [11] 罗莎, 王雪, 刘黎洁, 等. 99mTc-奥曲肽SPECT/CT对活动期甲状腺相关性眼病治疗的效果评价[J]. 眼科, 2013, 22(5): 309-12. https://www.cnki.com.cn/Article/CJFDTOTAL-YAKE201305011.htm [12] 段炼, 李险峰, 陆克义, 等. 99Tcm-奥曲肽眼眶显像在甲状腺相关眼病中的临床应用[J]. 中华眼科杂志, 2006, 42(12): 309-12. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHYK200612007.htm [13] 孙斌, 姚国敏, 段春青, 等. 甲状腺相关性眼病眶部99Tcm-生长抑素类似物受体显像与CAS评分的相关性研究[J]. 中国实用眼科杂志, 2008, 26(12): 1305-8. doi: 10.3760/cma.j.issn.1006-4443.2008.12.007 [14] Epstein FH, Bahn RS, Heufelder AE. Pathogenesis of Graves' ophthalmopathy[J]. N Engl J Med, 1993, 329(20): 1468-75. doi: 10.1056/NEJM199311113292007 [15] Dong F, Li L, Bian YZ, et al. Standardized uptake value using thyroid quantitative SPECT/CT for the diagnosis and evaluation of Graves' disease: a prospective multicenter study[J]. Biomed Res Int, 2019, 2019: 1-8. [16] 刘丹, 许雪亮, 文丹, 等. 99mT-DTPA眼眶SPECT/CT对甲状腺相关性眼病炎性活动的评价[J]. 中南大学学报: 医学版, 2018, 43(4): 457-60. https://www.cnki.com.cn/Article/CJFDTOTAL-HNYD201804024.htm [17] Liu D, Xu XL, Wang S, et al. 99mTc-DTPA SPECT/CT provided guide on triamcinolone therapy in Graves' ophthalmopathy patients[J]. Int Ophthalmol, 2020, 40(3): 553-61. doi: 10.1007/s10792-019-01213-6 [18] 杨宝军, 李险峰, 陆克义, 等. 99Tcm-二亚乙基三胺五乙酸与99Tcm-奥曲肽眼眶显像在甲状腺相关性眼病中的对比研究[J]. 国际放射医学核医学杂志, 2009, 33(1): 22-5. [19] Szumowski P, Abdelrazek S, Żukowski Ł, et al. Efficacy of 99mTc-DTPA SPECT/CT in diagnosing orbitopathy in Graves' disease[J]. BMC Endocr Disord, 2019, 19(1): 10. doi: 10.1186/s12902-019-0340-0 [20] Galuska L, Barna SK, Varga J, et al. The role of 99mTc-DTPA retrobulbar SPECT in staging and follow-up of Graves' orbitopathy[J]. Nucl Med Rev Cent East Eur, 2018, 21(1): 54-8. doi: 10.5603/NMR.a2018.0005 [21] Szumowski P, Abdelrazek S, Żukowski Ł, et al. Efficacy of 99mTc-DTPA SPECT/CT in diagnosing orbitopathy in Graves' disease[J]. BMC Endocr Disord, 2019, 19(1): 10. doi: 10.1186/s12902-019-0340-0 [22] Tang MT, Zeng XY, Li Y, et al. The application of 99Tcm-DTPA orbital SPECT/CT in staging evaluation of thyroid associated ophthalmopathy[J]. Zhonghua Yan Ke Za Zhi, 2021, 57(11): 830-6. [23] 蒋承志, 李新辉, 邓豪余, 等. 99mTc-DTPA眼眶SPECT/CT显像非靶区及阈值的选择在甲状腺相关性眼病中的应用[J]. 中南大学学报: 医学版, 2018, 43(8): 869-74. https://www.cnki.com.cn/Article/CJFDTOTAL-HNYD201808009.htm [24] 郭悦, 姚稚明, 刘秀芹, 等. 99Tcm-DTPA SPECT/CT眼眶显像评价甲状腺相关性眼病活动性: 与临床活动性评分及MRI的对比分析[J]. 国际放射医学核医学杂志, 2019(5): 416-21. https://www.cnki.com.cn/Article/CJFDTOTAL-DDYI202130055.htm